Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fumarates | 6 | 2016 | 131 | 1.210 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 11 | 2024 | 1516 | 1.100 |
Why?
|
Amides | 6 | 2016 | 449 | 1.050 |
Why?
|
Renin | 5 | 2016 | 641 | 0.930 |
Why?
|
Angiotensin Receptor Antagonists | 8 | 2024 | 1039 | 0.860 |
Why?
|
Heart Failure | 20 | 2024 | 11670 | 0.790 |
Why?
|
Enalapril | 4 | 2016 | 312 | 0.700 |
Why?
|
Rhabdomyolysis | 1 | 2020 | 152 | 0.640 |
Why?
|
Ehrlichiosis | 1 | 2018 | 28 | 0.610 |
Why?
|
Tetrazoles | 7 | 2024 | 909 | 0.600 |
Why?
|
Pancytopenia | 1 | 2018 | 102 | 0.570 |
Why?
|
Renin-Angiotensin System | 4 | 2016 | 737 | 0.550 |
Why?
|
Pyoderma Gangrenosum | 1 | 2017 | 84 | 0.540 |
Why?
|
Genital Diseases, Female | 1 | 2017 | 192 | 0.540 |
Why?
|
Stroke Volume | 16 | 2024 | 5496 | 0.540 |
Why?
|
Acidosis | 1 | 2017 | 268 | 0.500 |
Why?
|
Biphenyl Compounds | 7 | 2024 | 1007 | 0.500 |
Why?
|
Antihypertensive Agents | 5 | 2023 | 2024 | 0.490 |
Why?
|
Hemofiltration | 1 | 2015 | 59 | 0.480 |
Why?
|
Carbamates | 1 | 2016 | 191 | 0.470 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2017 | 370 | 0.460 |
Why?
|
Hematinics | 3 | 2021 | 282 | 0.460 |
Why?
|
Acetaminophen | 1 | 2017 | 554 | 0.430 |
Why?
|
Ramipril | 2 | 2024 | 102 | 0.410 |
Why?
|
Diuretics | 1 | 2015 | 610 | 0.390 |
Why?
|
Hypolipidemic Agents | 1 | 2015 | 609 | 0.370 |
Why?
|
Heart Failure, Systolic | 2 | 2013 | 135 | 0.360 |
Why?
|
Ventricular Function, Left | 8 | 2022 | 3879 | 0.350 |
Why?
|
Medicine | 1 | 2018 | 942 | 0.330 |
Why?
|
Dyspnea | 1 | 2017 | 1347 | 0.330 |
Why?
|
Neprilysin | 2 | 2019 | 478 | 0.330 |
Why?
|
Drug Combinations | 6 | 2024 | 2048 | 0.320 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 1141 | 0.310 |
Why?
|
Stroke | 4 | 2022 | 9758 | 0.310 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1924 | 0.300 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2020 | 2155 | 0.290 |
Why?
|
Anemia | 3 | 2021 | 1509 | 0.290 |
Why?
|
Piperidines | 1 | 2016 | 1656 | 0.290 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2022 | 12148 | 0.280 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1866 | 0.280 |
Why?
|
Erythropoietin | 2 | 2013 | 719 | 0.270 |
Why?
|
Double-Blind Method | 14 | 2024 | 12341 | 0.270 |
Why?
|
Cholesterol | 1 | 2015 | 2904 | 0.270 |
Why?
|
Hospitalization | 13 | 2024 | 10721 | 0.260 |
Why?
|
Terminal Care | 1 | 2018 | 1761 | 0.260 |
Why?
|
Anticoagulants | 2 | 2023 | 4812 | 0.250 |
Why?
|
Spironolactone | 2 | 2022 | 412 | 0.240 |
Why?
|
Naphthyridines | 1 | 2024 | 143 | 0.220 |
Why?
|
Blood Glucose | 2 | 2016 | 6391 | 0.220 |
Why?
|
Cerebral Hemorrhage | 1 | 2015 | 2656 | 0.220 |
Why?
|
Glomerular Filtration Rate | 3 | 2024 | 2177 | 0.210 |
Why?
|
Mass Screening | 2 | 2016 | 5428 | 0.210 |
Why?
|
Hemorrhage | 1 | 2015 | 3424 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
Atrial Fibrillation | 2 | 2023 | 5127 | 0.190 |
Why?
|
Nitric Oxide Synthase | 1 | 2004 | 908 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6484 | 0.190 |
Why?
|
Picolinic Acids | 1 | 2021 | 50 | 0.180 |
Why?
|
Natriuretic Peptides | 1 | 2022 | 155 | 0.180 |
Why?
|
Carbon Monoxide | 1 | 2004 | 547 | 0.180 |
Why?
|
Macula Lutea | 1 | 2022 | 177 | 0.180 |
Why?
|
Condylomata Acuminata | 1 | 2020 | 75 | 0.180 |
Why?
|
Urea Cycle Disorders, Inborn | 1 | 2020 | 32 | 0.180 |
Why?
|
Vasodilation | 1 | 2004 | 962 | 0.170 |
Why?
|
Pancreatitis, Chronic | 1 | 2023 | 289 | 0.170 |
Why?
|
Prediabetic State | 1 | 2016 | 545 | 0.170 |
Why?
|
Stress Disorders, Traumatic | 1 | 2020 | 50 | 0.170 |
Why?
|
Forensic Medicine | 1 | 2020 | 64 | 0.170 |
Why?
|
Humans | 49 | 2024 | 761572 | 0.170 |
Why?
|
Aged | 24 | 2024 | 169310 | 0.170 |
Why?
|
Hyperammonemia | 1 | 2020 | 76 | 0.170 |
Why?
|
Hematologic Tests | 1 | 2020 | 239 | 0.160 |
Why?
|
Middle Aged | 27 | 2024 | 220920 | 0.160 |
Why?
|
Registries | 1 | 2015 | 8224 | 0.160 |
Why?
|
Creatine Kinase | 1 | 2020 | 685 | 0.150 |
Why?
|
Weight Loss | 2 | 2021 | 2684 | 0.150 |
Why?
|
Patient Discharge | 2 | 2022 | 3443 | 0.150 |
Why?
|
Anaplasma phagocytophilum | 1 | 2018 | 37 | 0.150 |
Why?
|
Glycine | 1 | 2021 | 663 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 218 | 0.150 |
Why?
|
Myocardial Infarction | 5 | 2024 | 11461 | 0.140 |
Why?
|
Endemic Diseases | 1 | 2018 | 190 | 0.140 |
Why?
|
Female | 30 | 2024 | 392686 | 0.140 |
Why?
|
Whipple Disease | 1 | 2016 | 20 | 0.140 |
Why?
|
Treatment Failure | 4 | 2016 | 2644 | 0.140 |
Why?
|
Anus Neoplasms | 1 | 2020 | 329 | 0.140 |
Why?
|
Arthralgia | 1 | 2020 | 461 | 0.130 |
Why?
|
Doxycycline | 1 | 2018 | 344 | 0.130 |
Why?
|
Aftercare | 1 | 2022 | 914 | 0.130 |
Why?
|
Exanthema | 1 | 2020 | 503 | 0.130 |
Why?
|
Male | 30 | 2024 | 360842 | 0.120 |
Why?
|
Creatinine | 2 | 2024 | 1899 | 0.120 |
Why?
|
Cardiovascular Diseases | 7 | 2021 | 15501 | 0.120 |
Why?
|
Pyridones | 1 | 2020 | 809 | 0.120 |
Why?
|
Cause of Death | 2 | 2022 | 3683 | 0.120 |
Why?
|
Benzamides | 1 | 2020 | 1370 | 0.120 |
Why?
|
Insulin-Secreting Cells | 1 | 2021 | 901 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1475 | 0.110 |
Why?
|
Pancreatitis | 1 | 2021 | 1096 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12975 | 0.110 |
Why?
|
Rheumatic Diseases | 1 | 2021 | 649 | 0.110 |
Why?
|
Endophthalmitis | 1 | 2016 | 260 | 0.110 |
Why?
|
Peptides | 1 | 2015 | 4358 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2021 | 768 | 0.110 |
Why?
|
Glucose Tolerance Test | 1 | 2016 | 1178 | 0.110 |
Why?
|
Fatigue | 1 | 2020 | 1552 | 0.110 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 3085 | 0.110 |
Why?
|
Acute Coronary Syndrome | 1 | 2015 | 2190 | 0.100 |
Why?
|
Hypertension | 2 | 2023 | 8540 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2017 | 857 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 348 | 0.100 |
Why?
|
Glucose Intolerance | 1 | 2016 | 575 | 0.100 |
Why?
|
Refugees | 1 | 2020 | 596 | 0.100 |
Why?
|
Inpatients | 1 | 2023 | 2548 | 0.090 |
Why?
|
Risk Assessment | 3 | 2021 | 23996 | 0.090 |
Why?
|
Bariatric Surgery | 1 | 2021 | 992 | 0.090 |
Why?
|
Captopril | 1 | 2011 | 265 | 0.090 |
Why?
|
Child Abuse | 1 | 2020 | 1077 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12463 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1796 | 0.090 |
Why?
|
Obesity, Morbid | 1 | 2021 | 1277 | 0.090 |
Why?
|
Fever | 1 | 2018 | 1618 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1667 | 0.080 |
Why?
|
Pyrazoles | 1 | 2020 | 2009 | 0.080 |
Why?
|
Influenza, Human | 1 | 2021 | 1521 | 0.080 |
Why?
|
Acute Disease | 2 | 2023 | 7237 | 0.080 |
Why?
|
Mortality | 1 | 2021 | 2901 | 0.080 |
Why?
|
Single-Blind Method | 2 | 2019 | 1574 | 0.080 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 431 | 0.080 |
Why?
|
Aspirin | 1 | 2020 | 3133 | 0.080 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6075 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2020 | 1613 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2020 | 2751 | 0.080 |
Why?
|
Medication Adherence | 1 | 2020 | 2176 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2021 | 2118 | 0.080 |
Why?
|
Risk Factors | 6 | 2023 | 74213 | 0.080 |
Why?
|
Pyridines | 1 | 2020 | 2875 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2021 | 3963 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5841 | 0.070 |
Why?
|
Blood Pressure | 3 | 2023 | 8481 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5293 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2243 | 0.070 |
Why?
|
Treatment Outcome | 8 | 2024 | 64684 | 0.070 |
Why?
|
Kidney | 3 | 2024 | 7047 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10212 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2016 | 6312 | 0.070 |
Why?
|
Hemoglobins | 2 | 2021 | 1526 | 0.060 |
Why?
|
Follow-Up Studies | 7 | 2024 | 39107 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8528 | 0.060 |
Why?
|
Thromboembolism | 2 | 2021 | 995 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14607 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3245 | 0.060 |
Why?
|
Massachusetts | 1 | 2018 | 8830 | 0.060 |
Why?
|
Pediatrics | 1 | 2020 | 3589 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4591 | 0.060 |
Why?
|
Prospective Studies | 5 | 2021 | 54426 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58986 | 0.060 |
Why?
|
Adult | 8 | 2023 | 221203 | 0.060 |
Why?
|
Tetraethylammonium | 1 | 2004 | 55 | 0.060 |
Why?
|
Nitroarginine | 1 | 2004 | 66 | 0.060 |
Why?
|
Hypotension | 2 | 2021 | 879 | 0.060 |
Why?
|
Oxadiazoles | 1 | 2004 | 94 | 0.060 |
Why?
|
Nitroprusside | 1 | 2004 | 272 | 0.060 |
Why?
|
Nitric Oxide Donors | 1 | 2004 | 125 | 0.060 |
Why?
|
Pia Mater | 1 | 2004 | 87 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4618 | 0.060 |
Why?
|
Potassium Channel Blockers | 1 | 2004 | 161 | 0.060 |
Why?
|
Young Adult | 3 | 2020 | 59255 | 0.060 |
Why?
|
Body Mass Index | 1 | 2021 | 12954 | 0.050 |
Why?
|
Primary Health Care | 1 | 2020 | 4686 | 0.050 |
Why?
|
Arterioles | 1 | 2004 | 250 | 0.050 |
Why?
|
Cyclic GMP | 1 | 2004 | 395 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7391 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7407 | 0.050 |
Why?
|
Quinoxalines | 1 | 2004 | 296 | 0.050 |
Why?
|
Death, Sudden, Cardiac | 1 | 2010 | 1555 | 0.050 |
Why?
|
Cerebral Arteries | 1 | 2004 | 490 | 0.050 |
Why?
|
Angina, Unstable | 1 | 2015 | 888 | 0.050 |
Why?
|
Prognosis | 1 | 2022 | 29629 | 0.050 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2004 | 705 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9177 | 0.050 |
Why?
|
Death, Sudden | 1 | 2022 | 301 | 0.050 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 179 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 411 | 0.040 |
Why?
|
Ammonia | 1 | 2020 | 237 | 0.040 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2021 | 173 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 422 | 0.040 |
Why?
|
Lipase | 1 | 2021 | 325 | 0.040 |
Why?
|
Cohort Studies | 2 | 2020 | 41493 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2023 | 774 | 0.040 |
Why?
|
Hospitals | 2 | 2023 | 3882 | 0.040 |
Why?
|
Length of Stay | 2 | 2023 | 6426 | 0.040 |
Why?
|
American Heart Association | 1 | 2023 | 1039 | 0.040 |
Why?
|
Ferritins | 1 | 2021 | 598 | 0.040 |
Why?
|
Urea | 1 | 2020 | 443 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10090 | 0.040 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.040 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2004 | 1492 | 0.040 |
Why?
|
Glucosides | 1 | 2022 | 512 | 0.040 |
Why?
|
Research Design | 3 | 2011 | 6180 | 0.040 |
Why?
|
Orchitis | 1 | 2016 | 35 | 0.030 |
Why?
|
Epididymitis | 1 | 2016 | 37 | 0.030 |
Why?
|
Fluorescein Angiography | 1 | 2022 | 1059 | 0.030 |
Why?
|
Shock, Septic | 1 | 2013 | 768 | 0.030 |
Why?
|
Medical History Taking | 1 | 2020 | 774 | 0.030 |
Why?
|
Retinal Vessels | 1 | 2022 | 852 | 0.030 |
Why?
|
Sex Distribution | 1 | 2021 | 2281 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2022 | 916 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 80646 | 0.030 |
Why?
|
Ceftriaxone | 1 | 2016 | 175 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6815 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2004 | 2135 | 0.030 |
Why?
|
Age Distribution | 1 | 2021 | 2880 | 0.030 |
Why?
|
Patient Readmission | 2 | 2023 | 3271 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2020 | 1119 | 0.030 |
Why?
|
Swine | 1 | 2004 | 5915 | 0.030 |
Why?
|
Physical Examination | 1 | 2020 | 1255 | 0.030 |
Why?
|
HIV Infections | 1 | 2020 | 17352 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3713 | 0.030 |
Why?
|
Brain | 1 | 2020 | 27120 | 0.030 |
Why?
|
Myositis | 1 | 2016 | 271 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3306 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4021 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3579 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36429 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2020 | 1334 | 0.020 |
Why?
|
Resilience, Psychological | 1 | 2020 | 788 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2011 | 1723 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4431 | 0.020 |
Why?
|
Adolescent | 2 | 2020 | 88324 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2521 | 0.020 |
Why?
|
Time Factors | 3 | 2016 | 39970 | 0.020 |
Why?
|
Heart Rate | 1 | 2023 | 4195 | 0.020 |
Why?
|
Comorbidity | 1 | 2016 | 10508 | 0.020 |
Why?
|
Arthritis | 1 | 2016 | 680 | 0.020 |
Why?
|
Chronic Disease | 1 | 2016 | 9319 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2020 | 6019 | 0.020 |
Why?
|
Sodium Chloride, Dietary | 1 | 2011 | 293 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2021 | 3826 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2022 | 2917 | 0.020 |
Why?
|
Prevalence | 1 | 2016 | 15732 | 0.020 |
Why?
|
Seizures | 1 | 2020 | 2957 | 0.020 |
Why?
|
Aldosterone | 1 | 2011 | 870 | 0.020 |
Why?
|
United States | 3 | 2023 | 72335 | 0.020 |
Why?
|
Placebos | 1 | 2010 | 1667 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.020 |
Why?
|
Syndrome | 1 | 2010 | 3267 | 0.010 |
Why?
|
Europe | 1 | 2010 | 3422 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13510 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15843 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22176 | 0.010 |
Why?
|
Outpatients | 1 | 2010 | 1597 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26127 | 0.010 |
Why?
|
Hemodynamics | 1 | 2010 | 4160 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10766 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13367 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 42230 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2010 | 12059 | 0.010 |
Why?
|
Incidence | 1 | 2014 | 21355 | 0.010 |
Why?
|
Animals | 1 | 2004 | 168467 | 0.010 |
Why?
|
Child | 1 | 2020 | 80156 | 0.010 |
Why?
|
Concepts
(263)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_